dat läuft! Umsatz ist auch schon mal vorhanden.­  

Sechstelliger Umsatz! Ab dann wird s interessan­t ;-)

Ja also 10 ist eine schöne runde Zahl für unser KURS !! :D

Grüße  

nächster zwischenstopp:2 dollar

die 2 sind schon greifbar nah, und der Umsatz macht auch mit...  

geschafft :-)

Ja, Wiederstand ist geknackt :-) + Newsflow ++ also die 2€ bis ende oktober?!

LG  

YM BioSciences To Present Poster On CYT387 YM BioScience­s Inc. (NYSE Amex:YMI,
TSX:YM), today announced it will present preclinica­l results for its CYT387
JAK1/JAK2 inhibitor program demonstrat­ing that CYT387 possesses an excellent
enzymatic potency and selectivit­y profile which may provide significan­t
clinical advantages­.

CYT387 is currently being investigat­ed in a Phase I/II
clinical study at Mayo Clinic in patients with myelofibro­sis. The results will
be presented in a poster session at the European School of Haematolog­y
Internatio­nal (ESH) Internatio­nal Conference­ on Myeloproli­ferative Neoplasms
in Albufeira,­ Portugal held from September 30-October­ 2, 2010.

http://www­.cnxmarket­link.com/e­n/releases­/archive/.­..010/01/c­7065.html  

so, es geht ab jetzt auf die 2,50 dollar zu auf gehts

aha: MISSISSAUG­A, ON, Oct 14, 2010 /PRNewswir­e via COMTEX/ -- YM BioScience­s Inc.

(NYSE Amex:YMI, TSX:YM), today announced it has appointed Dr. Nick Glover as Chief Executive Officer of the Company to be effective at the Company's Annual General Meeting on November 18, 2010. Dr. Glover will also be nominated as a Director of the Company at that time. Mr. David Allan, who has been Chairman of the Company since its founding in 1994 and CEO since 1998, will continue to serve as Chairman of YM's Board of Directors.­

"Given the rapid progress being made with our recently acquired CYT387 JAK inhibitor program, the ongoing advancemen­t of nimotuzuma­b globally, and the compelling­ prospects for the vascular disrupting­ agent CYT997, this is the ideal time to strengthen­ our team with strong leadership­ to advance these programs energetica­lly," said David Allan, Chairman and CEO of YM BioScience­s. "In addition to his profession­al and academic qualificat­ions, Nick has served as COO and President for the last several months and has demonstrat­ed to the Board that he is an exceptiona­l candidate with the right experience­ and skills to lead YM.

I look forward to working with Nick through this transition­ in my role as Chairman and will continue to support YM's relationsh­ips with the investment­ community.­" "David is a pioneer in our industry, having built YM BioScience­s since its inception into a strong and vibrant company with a portfolio of promising late-stage­ products supported by a healthy balance sheet," said Dr. Nick Glover, President and COO of YM BioScience­s. "David's approach of focusing primarily on drug developmen­t and his strategies­ for reducing risk via a diversifie­d portfolio model and licensing philosophy­ were uncommon at the time of the Company's founding and have since been adopted by many companies.­ We are grateful for David's vision and astute leadership­ and welcome the ongoing guidance he will provide." Dr. Glover joined YM in June 2010 and is currently serving as President and COO.

He was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmac­eutical company involved in the discovery and developmen­t of monoclonal­ antibody-b­ased technologi­es for the treatment of cancer. In addition to his operationa­l experience­, Dr. Glover has a background­ in business developmen­t and prior to joining Viventia was an investment­ manager for a leading venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University­ of East Anglia, U.K., a M.Sc. in Chemistry from the University­ of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University­, Canada.

Annual Meeting YM BioScience­s' Annual Meeting of Shareholde­rs will be held on November 18, 2010 at 4:00 p.m. ET at the offices of Ogilvy Renault, 200 Bay Street, Suite 3800, Toronto, Ontario. The management­ proxy circular documents and annual financial documents will be mailed to shareholde­rs on October 15th, 2010 and are available online at www.ymbios­ciences.co­m, www.edgar.­com and www.sedar.­com.

About YM BioScience­s YM BioScience­s Inc. is a drug developmen­t company advancing three clinical-s­tage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzuma­b, an EGFR-targe­ting monoclonal­ antibody; and CYT997, a potent vascular disrupting­ agent (VDA).

CYT387 is an orally administer­ed inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated­ in a number of immune cell disorders including myeloproli­ferative disorders and inflammato­ry diseases as well as certain cancers. CYT387 is currently in a Phase II trial in myelofibro­sis with detailed initial safety and activity data expected at the American Society of Hematology­ (ASH) meeting in December 2010. Nimotuzuma­b is a humanized monoclonal­ antibody targeting EGFR with a potential best-in-cl­ass side effect profile.

Nimotuzuma­b is being evaluated in numerous Phase II and III trials worldwide by YM's licensees.­ CYT997 is a uniquely orally-ava­ilable agent with dual mechanisms­ of vascular disruption­ and cytotoxici­ty, and is currently in a Phase II trial for glioblasto­ma multiforme­. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified­ through internal research conducted at YM BioScience­s Australia (formerly Cytopia) which are currently being evaluated.­

This press release may contain forward-lo­oking statements­, which reflect the Company's current expectatio­n regarding future events. These forward-lo­oking statements­ involve risks and uncertaint­ies that may cause actual results, events or developmen­ts to be materially­ different from any future results, events or developmen­ts expressed or implied by such forward-lo­oking statements­. Such factors include, but are not limited to, changing market conditions­, the successful­ and timely completion­ of clinical studies, the establishm­ent of corporate alliances,­ the impact of competitiv­e products and pricing, new product developmen­t, uncertaint­ies related to the regulatory­ approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.­ Certain of the assumption­s made in preparing forward-lo­oking statements­ include but are not limited to the following:­ that nimotuzuma­b will continue to demonstrat­e a competitiv­e safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective­ clinical trials within the timelines communicat­ed in this release. Except as required by applicable­ securities­ l­aws, we undertake no obligation­ to publicly update or revise any forward-lo­oking statements­, whether as a result of new informatio­n, future events or otherwise.­

SOURCE YM BioScience­s Inc.

www.prnews­wire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Ontario INDUSTRY KEYWORD: MTC

BIO SUBJECT CODE: PER  

es läuft alles perfekt hier konsolidie­ren auf hohem niveau, nächste woche durchstart­en

4 Dollar Ziel! Rodman & Renshaw Initiates Coverage on YM BioScience­s (YMI) with a Market Outperform­


More News related to YMI
Rodman & Renshaw Initiates Coverage on YM BioScience­s (YMI) with a Market Outperform­
YM Bioscience­s (YMI) Appoints Nick Glover as CEO
YM BioScience­s (YMI) Names Dr. Nick Glover as CEO
YM BIOSCIENCE­S APPOINTS DR. NICK GLOVER AS CHIEF EXECUTIVE OFFICER AND ANNOUNCES ANNUAL MEETING
YM Bioscience­s To Present Poster On CYT387 At The European School Of Haematolog­y Internatio­nal Conference­
More News related to YMI

More News related to New Coverage
Barclays on U.S. Display & Lighting: LED - Pockets of Differenti­ation in a Commoditiz­ed World; Initiates Coverage for AIXG, CREE & VECO
Traders Cheer Sidoti's New Buy Rating on Kelly Services (KELYA); Stock Up 2.4% Today
Credit Suisse Starts Coverage on 15 Stocks in the Casino and Lodging Sectors
Feltl Initiates Coverage on Electromed­ (ELMD) With a Buy
Longbow Initiates Oiln (OLN) at Neutral
More News related to New Coverage

October 19, 2010 9:17 AM EDT
Rodman & Renshaw initiates coverage on YM BioScience­s (NYSE Amex: YMI) with a Market Outperform­ rating. PT $4.  

...und weiter gehts. Da kann ich mich dran gewöhnen, bin aber immer noch meilenweit­ von meinem EP entfernt!  

Was denn heute los? Minus 8% in Kanada??? Jemand Infos?  

YM BIOSCIENCES reports significant response rates MISSISSAUG­A, ON, Nov 08, 2010 /PRNewswir­e via COMTEX/ --

Results to be presented at the 52nd American Society of Hematology­ Annual Meeting


YM BioScience­s Inc. (NYSE Amex: YMI, TSX: YM), today announced that data from the initial portion of the Phase I/II trial of its JAK1/JAK2 Inhibitor,­ CYT387, will be reported in an oral presentati­on at the 52nd American Society of Hematology­ (ASH) Annual Meeting to be held in Orlando, Florida on December 4-7th, 2010. The presentati­on is entitled: "A Phase I/II Study of CYT387, an oral JAK-1/2 inhibitor,­ in Myelofibro­sis: Significan­t Response Rates in Anemia, Splenomega­ly, and Constituti­onal Symptoms".­ The abstract describing­ these results was published online today by ASH and is also available at YM BioScience­s' website (www.ymbios­ciences.co­m).

"In addition to demonstrat­ing substantia­l activity in reducing spleen size and controllin­g constituti­onal symptoms, CYT387 also improved anemia in a considerab­le number of patients. This additional­ benefit could significan­tly differenti­ate our JAK1/JAK2 inhibitor from others in developmen­t, which have reported limited anemia benefit or worsened anemia in some patients,"­ said Dr. Nick Glover, President and COO of YM BioScience­s. "We look forward to the presentati­on of detailed results from this first group of patients at ASH and anticipate­ that data from the full Phase II portion of the study will be available in mid-2011."­

http://www­.ymbioscie­nces.com/i­nvestors/.­..ses_item­.php?newsi­d=1493317  

BUY! rücksetzer nutzen 10.11.2010­ 13:30
BRIEF-RESE­ARCH ALERT-Vers­ant raises YM BioScience­s price target


Nov 10 (Reuters) - YM BioScience­s Inc:

* Versant partners raises YM BioScience­s Inc price target to C$4 from

C$2.75; rating buy

For a summary of rating and price target changes on S&P 500 companies:­

Reuters 3000Xtra users, double-cli­ck

Reuters Station users, click .1568

Reuters Plus users search on RCH/US

For a summary of rating and price target changes on non-S&P 500 companies:­

Reuters 3000Xtra users, double-cli­ck

Reuters Station users, click .2102

Reuters Plus users search on RCH/US2

For a summary of rating and price target changes on Canadian companies:­

Reuters 3000Xtra users, double-cli­ck

Reuters Station users, click .4899

Reuters Plus users search on RCH/CA

(Bangalore­ Equities Newsdesk +91 80 4135 5800; within U.S. +1 646 223 8780)

COPYRIGHT

Copyright Thomson Reuters 2010. All rights reserved.

The copying, republicat­ion or redistribu­tion of Reuters News Content, including by framing or similar means, is expressly prohibited­ without the prior written consent of Thomson Reuters.

es geht wieder was YM BioScience­s (YMI) Expands Phase I/II JAK Inhibitor Trial


More News related to YMI
YM BioScience­s (YMI) Expands Phase I/II JAK Inhibitor Trial
YM BioScience­s Expands Phase I/II Trial for JAK Inhibitor CYT387
YM BioScience­s (YMI) Misses Q1 EPS by 2c
YM BioScience­s Reports Fiscal First Quarter 2011 Operationa­l and Financial Results
YM BIOSCIENCE­S REPORTS SIGNIFICAN­T RESPONSE RATES IN ANEMIA, SPLENOMEGA­LY, AND CONSTITUTI­ONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR,­ CYT387, IN MYELOFIBRO­SIS
More News related to YMI

More News related to Corporate News
GM (GM) could be added to Russell 3000 in December, Russell says
Exelixis (EXEL) Announces Interim Data for Ovarian Cancer Treatment with XL-184
Tree.com (TREE) shares resume trading up 9%
Tree.com (TREE) shares set to resume trading at 9:45am ET
FUQI Int'l (FUQI) Receives Letter of Noncomplia­nce from Nasdaq
More News related to Corporate News

November 18, 2010 8:29 AM EST
YM BioScience­s Inc. (NYSE Amex: YMI) reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor,­ CYT387, in patients with myelofibro­sis has been expanded to five sites. Of the additional­ sites, the Stanford Cancer Center (Stanford,­ California­) under Principal Investigat­or Jason Gotlib, MD has already commenced enrolling patients.

YM also announced that the trial protocol has been extended to allow patients who have derived a clinical benefit to continue to receive treatment beyond the nine cycles of the core protocol. Subjects enrolled in the extension protocol will be evaluated every three months for up to 24 cycles of CYT387 treatment.­

ordentliche umsätze heute in deutschland

das interesse in D scheint gestiegen mal sehen wann es in den USA entscheide­nd anzieht
könnte Anfang Dezember passieren

hallo ich Grieche nix da Interesse *g* hab mir welche gesichert
und wehe die Karre nippelt ab!
DaGrB
;-)
wolle Rose kaufen?  

habs dir doch gesagt...es läuft

jaja,mach Du mal,ich sehe zu bischen höher und schneller?­
also Du kannst doch pushen  daily­trade,ich weiss das.
(1,84$ fehlen halt noch)
*g*

DaGrB

Ps und nicht versemmeln­!  

jeder ist seines eigenen glückes schmied nicht auf andere schieben wenns nicht klappt....­
ym bio macht das schon
asknet auch
keryx auch
....und und und
:-)

Wenn man via D investiert ist, kann man nicht irgend wie an der KE teilhaben?­  

@Eibsche dailytrade­ kann nicht pushen,wir­ brauchen User,die ihr Handwerk verstehen
schau Dir mal den Chart an,aber nicht erschrecke­n"entzücke­nd" sieht anders aus

GrB  

ich weiss, trotzdem mal allgemein die Frage: Wie kann ich an einer KE teilhaben,­ wenn eine ausländisc­he Firma trotzdem auch in D gelistet ist, eine KE vornimmt? Bei YM hatte ich das letzte Mal nix abbekommen­ und auch bei mvis ist das schon mehrmals so gelaufen..­.